suramin has been researched along with Eye Diseases in 15 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Eye Diseases: Diseases affecting the eye.
Excerpt | Relevance | Reference |
---|---|---|
"39 patients (Group A) with ocular onchocerciasis in the Sudan-savanna of north Cameroon were given 4-6 g of suramin and followed in detail over 1-2 years." | 9.04 | Effects of suramin on ocular onchocerciasis. ( Anderson, J; de C Marshall, TF; Fuglsang, H, 1976) |
"Treatment of onchocerciasis with suramin in an area of vector control led to an increased incidence of optic atrophy in treated patients compared to an untreated group." | 7.66 | The risk of optic atrophy following suramin treatment of ocular onchocerciasis. ( Rolland, A; Thylefors, B, 1979) |
"In 1959 a population of 638 persons over the age of seven years, suffering from heavy endemic onchocerciasis in the Sudan-Savannah of West Africa was examined, and approximately half were allotted to a group for treatment with suramin (up to a total of 4-2 g for healthy adults)." | 7.65 | The natural history of ocular onchocerciasis over a period of 14--15 years and the effect on this of a single course of suramin therapy. ( Budden, FH, 1976) |
"39 patients (Group A) with ocular onchocerciasis in the Sudan-savanna of north Cameroon were given 4-6 g of suramin and followed in detail over 1-2 years." | 5.04 | Effects of suramin on ocular onchocerciasis. ( Anderson, J; de C Marshall, TF; Fuglsang, H, 1976) |
"Treatment of onchocerciasis with suramin in an area of vector control led to an increased incidence of optic atrophy in treated patients compared to an untreated group." | 3.66 | The risk of optic atrophy following suramin treatment of ocular onchocerciasis. ( Rolland, A; Thylefors, B, 1979) |
"In 1959 a population of 638 persons over the age of seven years, suffering from heavy endemic onchocerciasis in the Sudan-Savannah of West Africa was examined, and approximately half were allotted to a group for treatment with suramin (up to a total of 4-2 g for healthy adults)." | 3.65 | The natural history of ocular onchocerciasis over a period of 14--15 years and the effect on this of a single course of suramin therapy. ( Budden, FH, 1976) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 14 (93.33) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rougemont, A | 1 |
Hien, M | 1 |
Thylefors, B | 5 |
Prost, A | 1 |
Rolland, A | 4 |
Hemady, RK | 1 |
Sinibaldi, VJ | 1 |
Eisenberger, MA | 1 |
Anderson, J | 4 |
Fuglsang, H | 4 |
Vingtain, P | 1 |
Lucot, J | 1 |
Chovet, M | 1 |
Budden, FH | 1 |
de C Marshall, TF | 1 |
Toufic, N | 1 |
Scheie, HG | 1 |
Shannon, RE | 1 |
Yanoff, M | 1 |
Gornig, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
Intervention | Female worms in nodule (Count of Units) |
---|---|
IVM + ALB | 127 |
IDA x 1 Dose | 142 |
IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
Intervention | Female worms in nodules (Count of Units) |
---|---|
IVM + ALB | 127 |
IDA x 1 Dose | 142 |
IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
Intervention | Female worms with intact uterus (Count of Units) |
---|---|
IVM + ALB | 41 |
IDA x 1 Dose | 40 |
IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
Intervention | Participants (Count of Participants) |
---|---|
IVM + ALB | 4 |
IDA x 1 Dose | 4 |
IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
Intervention | Participants (Count of Participants) |
---|---|
IVM + ALB | 0 |
IDA x 1 Dose | 0 |
IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
Intervention | Participants (Count of Participants) |
---|---|
IVM + ALB | 0 |
IDA x 1 Dose | 0 |
IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
Intervention | Count of microfilarae+ participants (Number) | ||
---|---|---|---|
Baseline | Month 12 | Month 18 | |
IDA x 1 Dose | 6 | 21 | 15 |
IDA x 3 Doses | 0 | 21 | 17 |
IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
---|---|---|---|---|
Baseline | Month 3 | Month 12 | Month 18 | |
IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
1 review available for suramin and Eye Diseases
Article | Year |
---|---|
Ocular onchocerciasis.
Topics: Diethylcarbamazine; Eye; Eye Diseases; Female; Glaucoma; Humans; Iritis; Keratitis; Male; Onchocerci | 1977 |
1 trial available for suramin and Eye Diseases
Article | Year |
---|---|
Effects of suramin on ocular onchocerciasis.
Topics: Adolescent; Adult; Anterior Chamber; Cornea; Eye Diseases; Female; Fundus Oculi; Glaucoma; Humans; I | 1976 |
13 other studies available for suramin and Eye Diseases
Article | Year |
---|---|
[Treatment of onchocerciasis with low, increasing doses of suramin in hyperendemic communities of Western Africa: 2. Clinical parasitologic and ophthalmologic results in a zone where transmission is controlled].
Topics: Adolescent; Adult; Burkina Faso; Child; Child, Preschool; Eye Diseases; Female; Humans; Infant; Infa | 1984 |
Basis for treatment and prevention of ocular onchocerciasis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Diethylcarbamazine; Drug Therap | 1982 |
[Basis of the treatment and prevention of ocular onchocerciasis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Africa; Antinematodal Agents; Diethylcarbamazine; Drug T | 1982 |
Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Corneal Diseases; Eye Diseases; Humans; Infus | 1996 |
Ocular onchocerciasis.
Topics: Diethylcarbamazine; Drug Therapy, Combination; Eye Diseases; Humans; Insect Control; Onchocerciasis; | 1978 |
The risk of optic atrophy following suramin treatment of ocular onchocerciasis.
Topics: Eye Diseases; Female; Humans; Male; Onchocerciasis; Optic Atrophy; Suramin | 1979 |
[Therapy of ocular onchocerciasis].
Topics: Anthelmintics; Diethylcarbamazine; Eye Diseases; Filaricides; Humans; Keratitis; Onchocerciasis; Sur | 1979 |
Further observations on the relationship between ocular onchocerciasis and the head nodule, and on the possible benefit of nodulectomy.
Topics: Cameroon; Dermatologic Surgical Procedures; Diethylcarbamazine; Eye; Eye Diseases; Female; Head; Hum | 1978 |
Further observations on the relationship between ocular onchocerciasis and the head nodule, and on the possible benefit of nodulectomy.
Topics: Cameroon; Dermatologic Surgical Procedures; Diethylcarbamazine; Eye; Eye Diseases; Female; Head; Hum | 1978 |
Further observations on the relationship between ocular onchocerciasis and the head nodule, and on the possible benefit of nodulectomy.
Topics: Cameroon; Dermatologic Surgical Procedures; Diethylcarbamazine; Eye; Eye Diseases; Female; Head; Hum | 1978 |
Further observations on the relationship between ocular onchocerciasis and the head nodule, and on the possible benefit of nodulectomy.
Topics: Cameroon; Dermatologic Surgical Procedures; Diethylcarbamazine; Eye; Eye Diseases; Female; Head; Hum | 1978 |
Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin.
Topics: Adolescent; Adult; Betamethasone; Child; Diethylcarbamazine; Drug Therapy, Combination; Eye Diseases | 1978 |
The natural history of ocular onchocerciasis over a period of 14--15 years and the effect on this of a single course of suramin therapy.
Topics: Adolescent; Adult; Child; Eye Diseases; Female; Follow-Up Studies; Humans; Male; Microfilariae; Onch | 1976 |
[The therapeutic difficulties of ocular onchocerciasis].
Topics: Arsenicals; Diethylcarbamazine; Eye Diseases; Humans; Onchocerciasis; Optic Nerve; Suramin; Thiabend | 1969 |
Onchocerciasis (ocular).
Topics: Biopsy; Child; Diagnosis, Differential; Diethylcarbamazine; Diphenhydramine; Eye Diseases; Female; H | 1971 |
[Eye involvement in onchocerciasis].
Topics: Adult; Biopsy; Complement Fixation Tests; Cornea; Diagnosis, Differential; Diethylcarbamazine; Eye D | 1967 |